CREG2
Protein CREG2
Also known as: CREG2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8IUH2
- Gene
- CREG2
- Ensembl
- ENSG00000175874
- Chromosome
- 2
- Canonical length
- 290 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in brain
OverviewNCBI Gene
Predicted to be located in Golgi apparatus; endoplasmic reticulum; and extracellular region. Predicted to be active in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
290 residues, UniProt reviewed canonical sequence.
>Q8IUH2|CREG2
1 MSVRRGRRPA RPGTRLSWLL CCSALLSPAA GYVIVSSVSW AVTNEVDEEL DSASTEEAMP
61 ALLEDSGSIW QQSFPASAHK EDAHLRPRAG AARARPPPAP PGMFSYRREG GQTASAPPGP
121 RLRAATARSL AHASVWGCLA TVSTHKKIQG LPFGNCLPVS DGPFNNSTGI PFFYMTAKDP
181 VVADLMKNPM ASLMLPESEG EFCRKNIVDP EDPRCVQLTL TGQMIAVSPE EVEFAKQAMF
241 SRHPGMRKWP RQYEWFFMKM RIEHIWLQKW YGGASSISRE EYFKAVPRKALocalizationUniProt · AlphaFold · HPA
Whether an antibody against CREG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 53 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 53 nTPM
- hippocampal formation: 19 nTPM
- amygdala: 14 nTPM
- basal ganglia: 6.8 nTPM
- hypothalamus: 4.5 nTPM
- midbrain: 2.7 nTPM
Single-cell type
- brain excitatory neurons: 91 nCPM
- brain inhibitory neurons: 46 nCPM
- other brain neurons: 32 nCPM
- ocular epithelial cells: 29 nCPM
- oligodendrocytes: 23 nCPM
- urothelial cells: 12 nCPM
Immune cell
- T-reg: 0.5 nTPM
- basophil: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- hippocampal formation: 89 nTPM
- cerebral cortex: 87 nTPM
- basal ganglia: 51 nTPM
- white matter: 49 nTPM
- amygdala: 46 nTPM
- pons: 27 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.5
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.58
- DepMap mean gene effect
- -0.09
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CREG2 as an antibody target. Whether an autoantibody or antibody against CREG2 could matter depends on whether native CREG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CREG2 is annotated as secreted, so native CREG2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CREG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...